Biotechnology

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

BioTesserae's BTC-001, a novel immunotherapy, proves safe in early trials, paving the way for more affordable and accessible treatment for dogs.

As Ontario hospitals face a financial crisis, a major innovation week aims to connect Canadian startups with global capital to solve healthcare's biggest challenges.

A new, non-invasive urine test from TOBY, Inc. has received FDA Breakthrough status, challenging blood-based rivals and promising a new era of accessible cancer detection.

Taiwanese biotech GlycoNex will begin human trials for GNX1021, a novel ADC that targets cancer's unique sugar coating to fight GI tumors.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

European non-profit ELRIG launches its first US conference, a free-to-attend event aiming to connect scientists and tackle intractable drug targets.

A landmark grant funds research into scaffold-free tissue, a revolutionary approach that could one day eliminate the need for many knee replacements.

The Jackson Laboratory appoints Steven Holstein to bridge science and capital, supercharging its new integrated platform for developing breakthrough therapies.

French firms Clean Cells and Naobios eye South Korea's booming biopharma sector, offering a rare integrated solution for viral vaccine and therapy development.

A global partnership aims to bring Atla-cel, a next-gen CAR-T therapy with low neurotoxicity, to children with leukaemia, potentially revolutionizing treatment.

In a market demanding quality, Keiretsu Forum-MST presents 11 vetted startups at the ACA Summit, showcasing the future of medtech, AI, and energy.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

With new funding, ImageneBio advances its unique OX40 inhibitor, IMG-007, for eczema and alopecia, but faces a divided Wall Street.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Backed by Maria Sharapova, new startup Amulet launches a science-first supplement aiming to optimize women's performance throughout their entire cycle.

Biotech firm Epitopea adds top expert Dr. Lisa Butterfield, validating its novel RNA vaccine approach targeting hidden cancer antigens for hard-to-treat tumors.

A family's personal journey with a rare disorder sparks a major investment in Quiver Bioscience's AI-powered therapy, aiming to treat Dup15q syndrome.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.